Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Since its founding in 1955, REYON Pharmaceutical has continued to innovate and take new leaps forward. Based on our research, production, and sales capabilities from API to Drug product using purely our own technology, we are leaping to become the global No. 1 bio & chemical pharmaceutical company in various areas including next-generation biopharmaceuticals, from gene therapy, to antibody therapy, cell therapy, and natural medicine.

Suzhou Ribo Life Science Co. Ltd. is a leading siRNA drug development company. Ribo has built strength on various siRNA drug development platforms, including target discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, etc. Particularly, Ribo has explored and evaluated varieties of siRNA delivery systems, such as liposome, polymer, dendrimer, protein and peptide complex. The company was founded on January 1, 2007 and is headquartered in Kunshan, china.

ToolGen, a biotechnology company, focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified that provides ready-to-use reagents for genome engineering experiments; gRNA/Cas9 plasmid that offers tools for genome editing experiment; and recombinant Cas9 protein that offers ready-to-use reagents for genome engineering experiments. ToolGen also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services. Its products are used in research applications. ToolGen began operation in 1999, with its headquarters in Seoul in South Korea. ToolGen is a subsidiary of NSN.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

MIBR is developing treatments and vaccines for rare diseases, autoimmune diseases, infectious diseases, cancers, etc. novel drug development using artificial intelligence pursuing the goals of developing new drugs and improving public health on a global scale

Kanglin Biotechnology (Hangzhou) Co., Ltd., established on 2015-08-07, Business scope includes technology development,Technical Services,technical consulting:Biotechnology,medical technology,biological reagent(In addition to drugs,Hazardous chemicals and precursor chemicals);drug development;wholesale,retail:Laboratory equipment and consumables(Removal of hazardous chemicals and precursor chemicals),laboratory equipment,equipment.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Changsha Aidikang Medical Laboratory Co., Ltd., established on 2010-04-19, The scope of business includes clinical cytomolecular genetics;clinical serology major;clinical immunology major;clinical chemistry laboratory;clinical microbiology major;Clinical Hematology;clinical body fluids;Class I medical device retail;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;computer software sales;Research and Development of Communication Technology;Computer Network System Engineering Services;Information Technology Consulting Services;Pathology;General cargo transportation(freight rental,Except for moving transportation);Dedicated transport of goods(Refrigerated).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)

Part of CSL Ltd., CSL Behring GmbH is a German company located in Marburg. The firm manufactures plasma protein bio therapeutics for the treatment of rare and major diseases. Michael Schröder, Lutz Guenter Bonacker and Craig Shelanskey are the current co-CEOs of the firm.

Baiyuete Biotechnology (Shanghai) Co., Ltd., established on 2011-09-01, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Import and export;Technology Import and Export;Offshore trade operation;Import and export agency;trade broker;Domestic trade agent;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);food sales(Only sell prepackaged food);Pet food and supplies retail;Pet Food and Supplies Wholesale;General merchandise sales;Cosmetics Wholesale;Cosmetics Retail;Chemical product sales(No licensed chemical products);Sales of Class I Medical Devices;Information Consulting Service(Not including licensing information consulting services);internet sales(Except for products that require a license for sale).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen Sanzhi Medical Technology Co., Ltd., established on 2017-04-17, Business scope includes general business items:Agricultural Technology,Biotechnology,new material technology,Promotion of Energy Saving Technology;Technical development of biological products;Technology development of biotechnology products;Science and Technology Information Consulting;Scientific research and technical service industry;Basic medical research and development,clinical research and development,Pharmaceutical R&D,Research and development of new anti-tumor drugs and technologies,Clinical research and development of new anti-tumor drugs and technologies,Small molecule drug synthesis research and development,Clinical biomarker development,Genetic Sequencing for Drug Evaluation Development,Research and development combining basic drug research and clinical medical research,Development of small molecule formulations,The licensing program is:

Shanghai Xinzhi Pharmaceutical Technology Co. Ltd. is a company headquartered in China that operates as biotechnology company that is engaged in the research and development and production of gene therapy drugs.

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Suzhou Bochuang Kangyuan Biotechnology Co., Ltd., established on 2015-11-24, Business scope includes biotechnology,medicine,Research on medical device products,Development and related technology development,technology transfer,technical consulting,Technical Services;Import and export business of goods and technology.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.